BACKGROUND: Thyroid cancer stem cells (CSCs) with ALDH and CD44 markers contribute to tumor growth and aggressiveness. We hypothesized that novel HSP90 inhibitors (KU711, WGA-TA) and 17-AAG can effectively target the function of thyroid CSCs in vitro and prevent migration and invasion. METHODS: Validated papillary (TPC1), follicular (FTC238,WRO), and anaplastic (ACT1) human thyroid cancer cell lines were treated with 3 HSP90 inhibitors. CSCs were quantified for aldehyde dehydrogenase by flow cytometry, CD44 expression by Western blot, and thyrosphere formation assay. Cellular pathway proteins were analyzed by Western blot and migration/invasion by Boyden-chambers. RESULTS: WGA-TA and 17-AAG induced HSP70 compensation (not observed with KU711) on Western blot in all cell lines (>1,000 fold vs controls). Only WGA-TA degraded HSP90-Cdc37 complexing by 60-70% versus controls. Expression of HSP90 clients β-catenin, BRAF, Akt, and phospho-Akt were significantly inhibited by WGA-TA treatment (50-80%, 50-90%, >80%, and >90%) compared with controls, KU711, and 17-AAG treatment. KU711 and WGA-TA decreased CD44 expression in all cell lines (25-60% vs controls/17-AAG), decreased ALDEFLOR activity by 69-98% (P < .005), and decreased sphere formation by 64-99% (P < .05 each). Finally, cell migration was decreased by 31-98%, 100%, and 30-38%, and invasion by 75-100%, 100%, and 47% by KU711,WGA-TA, and 17-AAG treatment (P < .05) each, respectively. CONCLUSION: KU711 and WGA-TA are novel HSP90 inhibitors targeting CSC function and inhibiting cell migration/invasion in differentiated and anaplastic thyroid cancers, warranting further translational evaluation in vivo.
BACKGROUND:Thyroid cancer stem cells (CSCs) with ALDH and CD44 markers contribute to tumor growth and aggressiveness. We hypothesized that novel HSP90 inhibitors (KU711, WGA-TA) and 17-AAG can effectively target the function of thyroid CSCs in vitro and prevent migration and invasion. METHODS: Validated papillary (TPC1), follicular (FTC238,WRO), and anaplastic (ACT1) humanthyroid cancer cell lines were treated with 3 HSP90 inhibitors. CSCs were quantified for aldehyde dehydrogenase by flow cytometry, CD44 expression by Western blot, and thyrosphere formation assay. Cellular pathway proteins were analyzed by Western blot and migration/invasion by Boyden-chambers. RESULTS:WGA-TA and 17-AAG induced HSP70 compensation (not observed with KU711) on Western blot in all cell lines (>1,000 fold vs controls). Only WGA-TA degraded HSP90-Cdc37 complexing by 60-70% versus controls. Expression of HSP90 clients β-catenin, BRAF, Akt, and phospho-Akt were significantly inhibited by WGA-TA treatment (50-80%, 50-90%, >80%, and >90%) compared with controls, KU711, and 17-AAG treatment. KU711 and WGA-TA decreased CD44 expression in all cell lines (25-60% vs controls/17-AAG), decreased ALDEFLOR activity by 69-98% (P < .005), and decreased sphere formation by 64-99% (P < .05 each). Finally, cell migration was decreased by 31-98%, 100%, and 30-38%, and invasion by 75-100%, 100%, and 47% by KU711,WGA-TA, and 17-AAG treatment (P < .05) each, respectively. CONCLUSION:KU711 and WGA-TA are novel HSP90 inhibitors targeting CSC function and inhibiting cell migration/invasion in differentiated and anaplastic thyroid cancers, warranting further translational evaluation in vivo.
Authors: Tianxin Yu; Xi Chen; Wen Zhang; Deannon Colon; Jiandang Shi; Dana Napier; Piotr Rychahou; Wange Lu; Eun Y Lee; Heidi L Weiss; B Mark Evers; Chunming Liu Journal: J Biol Chem Date: 2011-12-14 Impact factor: 5.157
Authors: R Hoshino; Y Chatani; T Yamori; T Tsuruo; H Oka; O Yoshida; Y Shimada; S Ari-i; H Wada; J Fujimoto; M Kohno Journal: Oncogene Date: 1999-01-21 Impact factor: 9.867
Authors: Patrick T Grogan; Kristina D Sleder; Abbas K Samadi; Huaping Zhang; Barbara N Timmermann; Mark S Cohen Journal: Invest New Drugs Date: 2012-11-06 Impact factor: 3.850
Authors: Kevin Shee; Jason D Wells; Matthew Ung; Riley A Hampsch; Nicole A Traphagen; Wei Yang; Stephanie C Liu; Megan A Zeldenrust; Liewei Wang; Krishna R Kalari; Jia Yu; Judy C Boughey; Eugene Demidenko; Arminja N Kettenbach; Chao Cheng; Matthew P Goetz; Todd W Miller Journal: Clin Cancer Res Date: 2019-09-26 Impact factor: 12.531
Authors: Chitra Subramanian; Peter T White; Rui Kuai; Avinaash Kalidindi; Valerie P Castle; James J Moon; Barbara N Timmermann; Anna Schwendeman; Mark S Cohen Journal: Surgery Date: 2018-05-09 Impact factor: 3.982
Authors: Chitra Subramanian; Rebecca Gorney; Ton Wang; Derek Ge; Nina Zhang; Ang Zuo; Brian S J Blagg; Mark S Cohen Journal: Surgery Date: 2020-07-24 Impact factor: 3.982